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Abstract 
Objective: A recent report indicates repetitive transcranial magnetic stimulation (rTMS) improves sleep in 
Parkinson’s disease (PD). The aim of this work is to evaluate the effect of 10 days rTMS on sleep 
parameters in PD patients. 
Methods: Double-blind, placebo-controlled design. Eighteen idiopathic PD patients completed the study. 
Sleep parameters were evaluated through actigraphy and the Parkinson’s Disease Sleep Scale (PDSS), 
along with depression (Hamilton Depression Rating Scale, HDS), and the Unified Parkinson’s Disease 
Rating Scale (UPDRS). Evaluations were carried out before treatment with rTMS (pre-evaluation, PRE), 
after the rTMS treatment programme (post-evaluation, POST), and one week after POST (POST-2). Nine 
PD patients received real rTMS and the other 9 received sham rTMS daily for 10 days, (100 pulses at 1 
Hz) applied with a large circular coil over the vertex. 
Results: Stimulation had no effect over actigraphic variables. Conversely PDSS, HDS, and UPDRS were 
significantly improved by the stimulation. Notably, however, these changes were found equally in groups 
receiving real or sham stimulation. 
Conclusions: rTMS, using our protocol, has no therapeutic value on the sleep of PD patients, when 
compared to appropriate sham controls. Future works assessing the possible therapeutic role of rTMS on 
sleep in PD should control the effect of placebo. 
Keywords: Parkinson. Sleep. Repetitive transcranial magnetic stimulation (rTMS). Actigraphy. 
Depression. Therapy 
1. Introduction 
Parkinson’s disease (PD) is almost invariably thought of as a disease of the motor system [1]. 
However, it is well documented that PD displays a whole range of non-motor signs, amongst which sleep 
disorders affect 74–98% of patients [2,3], though it seems all patients display alterations in the early 
phases of the disease [4]. It has been suggested that the course of such disturbances might be not directly 
related to the motor progression of the disease [5]. Given that sleep disorders (along with depression and 
loss of independence) are factors with the highest impact in quality of life of patients [6], investigation 
into the nature of this phenomenon is important. Sleep disorders in PD are well defined and can be 
subdivided into daytime and nocturnal occurrences [2,7]. Amongst the latter, light fragmented sleep is the 
most frequent subjective sleep complaint in PD [8]. Sleep disorders are associated with other non-motor 
symptoms of the disease, as there is a strong relationship between subjective sleep complaints and 
depression, particularly in PD [8]. 
The origin of sleep disorders in PD could be the result of side-effects of medication, as dopaminergic 
agonist has been shown to worsen sleep efficiency [9]. Secondly, there may be neurodegeneration of 
sleep regulating structures during the progression of the disease [2,7]. It also seems possible that the sleep 
disorders relate to dopaminergic function in parallel with non-dopaminergic dysfunction [10], e.g., light 
fragmentation sleep has been improved by dopaminergic treatment [11]; though other studies have 
reported sleep disorders only partially respond to dopaminergic treatment, as controlled released levodopa 
increases sleep time but has no effect on sleep fragmentation [12]. In contrast to motor symptoms for 
which several treatments are available, sleep disorders in PD are usually poorly recognized and treated 
[4]. 
Transcranial magnetic stimulation (TMS) is a technique useful for evaluating several 
neurophysiological parameters [13] and potentially treating non-motor [14] and motor disorders [15]. The 
therapeutic role of repetitive TMS (rTMS) is based on its ability to differentially modulate neural activity 
depending on stimulation parameters such as frequency [16], coil type [17], pulse waveform [18,19], or 
current direction [20]. This may be the reason that a single recent study (published whilst our work was in 
process) has shown beneficial changes to sleep following rTMS in PD [21]. The study showed that 10 
days of 5 Hz rTMS over the parietal cortex improved sleep efficiency and fragmentation index as 
assessed by actigraphy. These results are intriguing as they seem to suggest a possible therapeutic role for 
rTMS in improving sleep quality in PD, with the group receiving parietal stimulation compared to a 
control group receiving motor cortex stimulation. Interestingly, it has been reported that rTMS over the 
motor cortex induces an increase in slow wave activity (SWA) in subsequent sleep in a group of healthy 
subjects [22] so that given the small proportion of SWA in PD [23] the use of rTMS to improve sleep in 
PD is worth being explored. It has also been shown (again in healthy subjects [24]) that low-frequency 
rTMS increases SWA. 
Taking all the above into account, we decided to study the effect of 10 days low-frequency (1 Hz) 
rTMS applied over the vertex, previously used with apparent success on motor signs [25,26], using a 
diffuse large round coil applied on sleep (and depression) in PD, using a double-blind, placebo-controlled 
design. We hypothesized that rTMS, under the protocol tested, would have a positive impact on sleep 
disorders in PD. 
2. Methods 
2.1. Patients 
Nineteen PD patients started and 18 PD (9 real, 9 sham) patients completed the study. Inclusion 
criteria were primary diagnosis of Parkinson’s disease (based on medical records following established 
diagnostic criteria). Exclusion criteria were previous experience with TMS; implanted devices; pump-
based drug administration systems; history of seizures; dementia (MMSE <24); presence of dyskinesias 
disturbing stimulation; unpredictable motor fluctuations; and medication change within the last month 
before the start of experiment. One of the 19 PD patients who started the study withdrew for reasons 
unconnected to the study. The rest completed the protocol without complaint. Patients taking drugs to 
assist sleep or antidepressant were not included in the study (Fig. 1). 
Patients were required to complete all sessions and could not change their regime of medication 
throughout the study. Patients were enrolled into the programme in groups of up to 4 patients every 3 
weeks. Patients were randomly assigned to either receive real or sham stimulation during the sessions; 
however, the distribution of the two last sets of patients followed a counterbalance design (based on PRE 
UPDRS-score) in order to avoid an imbalance in the groups. The selection of UPDRS as criterion was 
based on previous reports showing that sleep disorders do not match motor progression of the disease [5]. 
2.2. General procedure 
Evaluations were carried out three times: pre-test, before the 10 stimulation sessions (PRE); post-test, 
after the stimulation programme (POST); and one week after POST (POST-2). Evaluation was performed 
by investigators blind to the whole design and was performed during patient ON periods as defined by 
neurological examination and patient’s confirmation. TMS (Monday–Friday for two weeks) was applied 
in the morning during patient-rated ON periods, between 1 and 2 h after medication intake, based on 
previous work reporting better effect of stimulation when applied during ON periods [27]. 
The protocol conformed to the Helsinki declaration and was approved by the ethics committee of the 
University of A Coruña. All patients were fully informed and signed consent forms. 
2.3. Evaluations 
2.3.1. Actigraphy 
We used the Actiwatch system (Actiwatch, CamNtech Ltd., Cambridge, UK) to register sleep 
parameters. Actigraphy is recognized as a useful tool for the assessment of sleep quality [28], which has 
been favourably compared to polysomnography [29]. It has also been shown to be suitable for assessing 
sleep quality in PD [9,30]. 
Patients wore the system, based on accelerometers built into wrist-worn activity watches which were 
attached to the wrist of the least affected side. Patients wore the system for a period of three days and 
three nights immediately before (PRE) and after the stimulation period (POST) and one week after POST 
(POST-2). Patients wore the watch all day, except during bathing. Patients were instructed to press the 
Actiwatch button when turning lights off and again when getting out of bed; a ‘‘sleep diary” was kept 
reflecting the times of getting into and out of bed, with other complementary data such as the number of 
times they got up during the night, etc. 
 
 
Fig. 1. Trial flow-chart. 
  
2.3.2. Parkinson’s Disease Sleep Scale (PDSS) 
The PDSS is a reliable scale for the assessment of subjective sleep complaints, specifically developed 
for PD [31,32]. This has been validated in its Spanish version [33] and successfully compared to other 
sleep assessment techniques [34]. The scale covers several sleep disorders related to the nocturnal and 
daytime manifestations of the disease. These are assessed by 15 items to be addressed using an analogue 
scale, toward a total score ranging from 0 to 150: the lower the score, the greater the sleep complaints. 
Patients were asked to complete the scale three times (at PRE, POST, and POST-2), in each case 
concerning the week preceding the test period. 
2.3.3. Hamilton Depression Scale (HDS) 
The HDS-17 [35], which has also been validated in Spanish [36], was used in order to assess 
depression. Evaluation again referred to the week preceding the test period. 
2.3.4. UPDRS 
The total score of the UPDRS was assessed. 
2.4. Stimulation 
TMS was applied using a round coil (see Apparatus) centred over the vertex. For each session, 100 
pulses were delivered in two trains of 50 pulses/train, applied at 1 Hz. One train was delivered clockwise 
and the other one anti-clockwise. We allowed a 5 min pause between trains. Intensity was set at 90% of 
the rest motor threshold (RMT), which was calculated every day before starting the stimulation. RMT 
was defined as the lowest intensity required to elicit a clear response of 50 µV peak-to-peak amplitude in 
5 out of 10 successive trials in the first dorsal interosseus of the less affected side. 
For sham stimulation two coils were used. One coil was not connected to the stimulator, and this coil 
was placed over the vertex, as the real coil would have been. The second coil was placed in direct contact 
to the first coil, but tilted 90º. In this way the patient could feel a coil flat over the head (as was expected 
from the description given to them prior to the test), but be unaware of the presence of a second, active 
coil (but able to appreciate the sensory input associated with the presence of a ‘‘coil”). During the sham 
protocol EMG settings were maintained and some single pulses were delivered (mimicking RMT 
determination) in order to make protocols appear identical. 
Therefore, the amount of time delivering stimulation per sessions in our protocol lasted the same as in 
a study by van Dijk et al. [21], since we both stimulated during 100 s/session; though given that our 
stimulation frequency was 1 Hz, following previous findings [24], stimulation blocks were different. 
2.5. Apparatus 
Transcranial magnetic stimulation: TMS stimulation was applied using a High Power 90 mm Round 
Coil powered by a Magstim Rapid device (The Magstim Company, Whiyland, UK). Motor evoked 
potentials (MEP) were registered using Ag/Cl surface electrodes fixed on the skin with a belly tendon 
montage. 
Actiwatch system: actigraphy recording is based on registration movement by the means of a piezo-
electric accelerometer (built into the wrist-watch-like device) that is designed to record the integral of 
intensity, amount and duration of movement in all directions. Activity is then converted to a measured in 
counts. Determination of sleep and wakefulness by the Actiwatch Sleep Analysis software relies on an 
algorithm which uses the activity data recorded by the device in a series of linked calculations. The 
algorithm looks at each data point from each epoch and those surrounding it and makes a total score 
based on these activity counts. 
2.6. Analysed variables 
The following variables were analysed in this study: 
Actigraphic variables (all their units are defined in the tables) 
– Immobility phases of 1 min (total and%): the number of immobility phases where the duration was 
only one minute; its percentage represents the proportion of immobility phases of 1 min with regard to 
the total number of immobility phases.  
– Number of sleep and wake bouts: the actual number of episodes of sleep and wakefulness 
– Mean length of sleep and wake bouts: total duration of sleep and wake by the corresponding number 
of sleep or wake bouts. 
– Mean length of immobility: the average length of all the immobile phases during the time in bed. 
– Number of immobile phases (total and%): the number of periods of continuous scores of zero being 
recorded in consecutive epochs. 
– Number of minutes immobile (total and%): the total number of minutes where a score of zero was 
recorded during the assumed sleep period; its percentage represents the percentage of time spent 
immobile during assumed sleep period. 
– Number of minutes moving (total and%): the total number of minutes where a score greater than zero 
was recorded during the assumed sleep period; its percentage represents the percentage of time spent 
moving during assumed sleep period. 
– Sleep latency: latency before sleep onset following bed-time. 
– Sleep efficiency: percentage of time spent asleep whilst in bed. 
– Movement and fragmentation index: the addition of percentage time spent moving and the percentage 
immobility phases of 1 min. It is an indicator of restlessness. 
PDSS, HDS, UPDRS: scores from each scale were introduced into the analysis. 
2.8. Data analysis 
To check homogeneity between groups before the start the stimulation protocol (at PRE), a Students 
‘‘t” for independent samples, was applied for each variable. 
Afterwards, to evaluate the effect of the stimulation, a two-way ANOVA with repeated measures was 
performed for each of the variables analysed. One within-subjects factor was defined, factor evaluation 
with 3 levels (PRE, POST, POST-2); this would therefore measure the effect of the protocol on the 
variables. The between subjects factor was the group (real stimulation or sham stimulation), which 
therefore was set to measure a possible placebo effect. 
During analysis the normality of distribution was checked by a K–S test. In the ANOVA analysis the 
degrees of freedom were corrected by applying the Greenhouse–Geisser correction when sphericity was 
violated. The SPSS package was used for statistical analysis and significance was set at p < 0.05. 
3. Results 
3.1. Groups homogeneity. Comparison at PRE values 
Groups were not significantly different for all variables at the beginning of the protocol. When the 
different variables were compared between the groups receiving real or sham stimulation, before starting 
the protocol, Student ‘‘t” for independent samples did not show any significant difference (see Table 1). 
3.2. Effect of the stimulation protocol 
The result of the rTMS protocol on the variables had two welldefined patterns of effects. Using the 
analysis rituals described, the UPDRS scores, HDS and PDSS were significantly improved following 
treatment (F(2, 32) = 13.077 p ≤ 0.001, F(2, 32) = 23.508 p ≤ 0.001 and F(1.412, 22.591) = 7.902 p = 
0.005, respectively), indicating that the treatment produced benefits across the whole population. In 
addition, the interaction Evaluation * Group showed no significant differences [for the measures UPDRS, 
HDS and PDSS; F(2, 32) = 0.704 p = 0.502, F(2, 32) = 0.389 p = 0.681 and F(1.412, 22.591) = 2.932 p = 
0.089, respectively; see Table 2], indicating a significant placebo effect. 
In addition, it is notable that no actigraphic variable was affected by the stimulation. This pattern was 
seen in both groups (as there was no significant interaction in Evaluation * Group). Therefore, it is clear 
that the rTMS protocol had no effect on these parameters (see Table 3). Also factor group for all the 
analysed variables was not significant either (see Tables 2 and 3).  
Table 1 
Characterization of groups before starting the stimulation protocol. 
 Real Sham t and p values 
Actigraphic variables    
Sleep efficiency (%) 87.423 (±5.692) 86.730 (±7.061) t(16) = 0.229 p = 0.822 
Sleep latency (s) 404.445 (±354.792) 225.964 (±287.964) t(16) = 1.172 p = 0.258 
Number of sleep bouts 25.554 (±11.392) 31.907 (±15.741) t(16) = 0.981 p = 0.341 
Mean Length of sleep bouts (s) 917.373 (±508.341) 860.482 (±519.519) t(16) = 0.235 p = 0.817 
Mean Length of wake bouts (s) 83.185 (±28.485) 83.000 (±36.825) t(16) = 0.012 p = 0.991 
Number of minutes immobile 372.445 (±97.965) 396.721 (±82.703) t(16) = 0.568 p = 0.578 
Number of minutes immobile (%) 86.247 (±4.000) 84.217 (±7.646) t(12.075) = 0.706 p = 0.494 
Number of minutes moving 57.075 (±16.898) 75.000 (±36.740) t(11.240) = 1.330 p = 0.210 
Number of minutes moving (%) 13.752 (±4.000) 15.782 (±7.646) t(12.075) = 0.706 p = 0.494 
Number of immobile phases 60.037 (±19.249) 68.777 (±33.112) t(16) = 0.685 p = 0.503 
Mean length of immobility (min) 7.043 (±2.980) 7.454 (±3.692) t(16) = 0.260 p = 0.798 
Immobility phase of 1 min (#) 18.556 (±8.795) 25.222 (±16.560) t(16) = 1.066 p = 0.302 
Immobility of 1 min (%) 29.706 (±7.890) 32.670 (±8.423) 
t(16) = 0.770 
p = 0.452 
 
Movement and fragmentation index 43.460 (±11.287) 48.451 (±16.004) t(16) = 0.765 p = 0.456 
HDS (score) 17.111 (±4.567) 14.555 (±5.433) t(16) = 1.080 p = 0.296 
PDSS (score) 104.641 (±27.318) 92.175 (±28.324) t(16) = 0.950 p = 0.356 
UPDRS (score) 50.333 (±10.452) 50.000 (±25.431) t(16) = 0.036 p = 0.971 
    
 
The table represents the value for each variable before starting the protocol. Lack of significant differences (real vs. sham) at the 
pre-test values means groups was comparable and homogeneous at the beginning of the programme. Means and standard deviations 
are displayed along with the p value. 
Abbreviations: HDS, Hamilton Depression Scale; PDSS, Parkinson’s Disease Sleep Scale; UPDRS, Unified Parkinson’s Disease 
Rating Scale. 
4. Discussion 
The main outcome of the study is that the protocol used has no therapeutic value as a therapy for sleep 
disorders in PD. Our results did not show any change in the sleep parameters objectively evaluated. The 
data does, however, display significant changes in the PDSS (a well designed scale used to assess 
subjective sleep complaints in PD) and in the score for depression and the UPDRS, all of which were 
positively affected. But in each of these cases improvement seems clearly attributable to a placebo 
response. The results from PDSS are complementary to those measured by actigraphy, as PDSS covers 
Parkinsonian-related sleep complaints displayed also during daytime; this reinforces the idea of a placebo 
response cause of improvements which do not appear in the ‘‘sleeping” patient. Interestingly, our data 
showed a significant improvement on measures of depression, also attributable to placebo response. 
The traditional view of Parkinson’s disease is based firmly upon the (more obvious) motor signs, and 
treatments have invariably been directed towards the goals of amelioration (quite rightly) of these major 
crippling symptoms. However, non-motor symptoms exist in Parkinsonian syndrome, which are now 
receiving more attention; amongst these, depression and sleep disorders significantly lower the sufferer’s 
quality of life. To our knowledge only one recent study [21] has reported the effect of rTMS on sleep 
parameters, which included an improvement in two out of seven actigraphic variables, fragmentation 
Table 2 
Effect of the stimulation on the UPDRS, HDRS, and PDSS. 
 PRE POST POST-2 Factor evaluation Factor group Evaluation * Group 
       
HDS (score) 15.833 (±5.043) 10.555 (±5.113) 10.500 (±4.617) F(2, 32) = 23.508 p 6 0.001 
F(1, 16) = 0.774 
p = 0.392 
F(2, 32) = 0.389 
p = 0.681 
PDSS (score) 98.408 (±27.746) 112.006 (±25.073) 110.813 (±23.083) F(1.412, 22.591) = 7.902 p = 0.005 
F(1, 16) = 0.033 
p = 0.859 
F(1.412, 22.591) = 2.932 
p = 0.089 
UPDRS (score) 50.166 (±18.862) 41.944 (±19.144) 39.222 (±18.405) F(2, 32) = 13.077 p 6 0.001 
F(1, 16) = 0.737 
p = 0.403 
F(2, 32) = 0.704 
p = 0.502 
       
 
The table represents the effect of factor evaluation (p value) along the whole protocol. Values for each variable are displayed at the beginning of the programme (PRE), after finishing the programme (POST), and one 
week after POST (POST-2). Values are shown for both groups pooled on the basis that significant interaction Evaluation * Group was never displayed, proving the effect was the same for both groups. Means and 
standard deviations are displayed, along with the p value.  
Abbreviations: HDS, Hamilton Depression Scale; PDSS, Parkinson’s Disease Sleep Scale; UPDRS, Unified Parkinson’s Disease Rating Scale. 
 
 
The table represents the effect of factor evaluation (p value) along the whole protocol. Values for each variable are displayed at the beginning of the programme (PRE), after finishing the programme (POST), and one 
week after POST (POST-2). Values are shown for two groups pooled on the basis that significant interaction Evaluation * Group was never displayed, proving the effect was the same for both groups. Means and 
standard deviations are displayed, along with the p value. 
Table 3 
Effect of the stimulation on the evaluated parameters of actigraphy. 
 PRE POST POST-2 Factor evaluation Factor group Evaluation * Group 
Sleep efficiency (%) 87.076 (±6.232) 85.497 (±8.788) 83.210 (±11.806) F(2, 32) = 1.739 p = 0.192 
F(1, 16) = 0.099 
p = 0.757 
F(2, 32) = 0.433 
p = 0.653 
Sleep latency (s) 315.205 (±326.636) 
502.629 
(±514.850) 
480.240 
(±627.189) 
F(2, 32)=1.141 
p = 0.332 
F(1, 16) = 0.893 
p = 0.359 
F(2, 32) = 0.588 
p = 0.561 
Number of sleep bouts 28.731 (±13.725) 28.602 (±13.401) 32.184 (±20.383) F(2, 32) = 1.087 p = 0.349 
F(1, 16) = 0.646 
p = 0.433 
F(2, 32) = 0.030 
p = 0.971 
Mean Length of sleep bouts (s) 888.927 (±499.473) 
1081.001 
(±594.033) 
1156.037 
(±942.232) 
F(2, 32) = 1.294 
p = 0.288 
F(1, 16) = 0.146 
p = 0.707 
F(2, 32) = 0.l62 
p = 0.851 
Mean Length of wake bouts (s) 83.092 (±31.938) 101.593 (±42.676) 101.592 (±47.672) F(2, 32) = 2.608 p = 0.089 
F(1, 16) = 0.409 
p = 0.532 
F(2, 32) = 0.489 
p = 0.618 
Number of minutes immobile 384.583 (±88.831) 
362.745 
(±101.171) 
350.268 
(±126.125) 
F(2, 32) = 1.130 
p = 0.336 
F(1, 16) = 0.000 
p = 0.985 
F(2, 32) = 0.413 
p = 0.665 
Number of minutes immobile (%) 85.232 (±6.011) 83.326 (±8.590) 77.962 (±21.417) F(1.063, 17.002) = 1.936 p = 0.182 
F(1, 16) = 0.990 
p = 0.334 
F(1.063, 17.002) = 0.701 
p = 0.423 
Number of minutes moving 66.037 (±29.234) 72.958 (±37.740) 92.888 (±78.166) F(1.120, 17.915) = 1.996 p = 0.175 
F(1, 16) = 1.673 
p = 0.214 
F(1.120, 17.915) = 0.584 
p = 0.473 
Number of minutes moving (%) 14.767 (±6.011) 16.673 (±8.590) 22.037 (±21.417) F(1.063, 17.002) = 1.936 p = 0.182 
F(1, 16) = 0.990 
p = 0.334 
F(1.063, 17.002) = 0.701 
p = 0.423 
Number of immobile phases 64.407 (±26.656) 68.332 (±33.386) 66.453 (±40.535) F(2, 32) = 0.192 p = 0.826 
F(1, 16) = 0.139 
p = 0.715 
F(2, 32) = 0.114 
p = 0.892 
Mean length of immobility (min) 7.248 (±3.262) 7.777 (±5.855) 7.535 (±6.236) F(2, 32) = 0.094 p = 0.910 
F(1, 16) = 0.001 
p = 0.972 
F(2, 32) = 0.848 
p = 0.438 
Immobility phase of 1 min (#) 21.889 (±13.312) 26.111 (±18.872) 24.675 (±19.865) F(2, 32) = 0.790 p = 0.462 
F(1, 16) = 0.502 
p = 0.489 
F(2, 32) = 0.062 
p = 0.940 
Immobility of 1 min (%) 31.188 (±8.062) 32.883 (±12.341) 37.246 (±19.374) F(1.422, 22.747) = 1.539 p = 0.235 
F(1, 16) = 0.770 
p = 0.393 
F(1.422, 22.747) = 0.542 
p = 0.530 
Movement and fragmentation index 
 45.955 (±13.677) 49.557 (±20.470) 59.284 (±40.181) 
F(1.179, 18.870) = 1.826 
p = 0.194 
F(1, 16) = 0.908 
p = 0.355 
F(1.179, 18.870) = 0.649 
p = 0.455 
index, and sleep efficiency in a group of patients receiving focal parietal stimulation. We were unable to reproduce their 
results. Most likely the differences accounting for this are methodological; for example, they applied rTMS at 5 Hz, 80% 
RMT; used a figure of eight coil over the motor vs. parietal cortex, both bilaterally; and the coil used in our study was a large 
round diffuse coil, not the same as van Dijk [21] (we did not try to replicate the study since ours was ongoing when van Dijk’s 
was published). The areas of cortical stimulation could also account for different results. Other more minor reasons could be 
considered (intensity differed for instance). Nevertheless, the main point seems to be that their data, unlike ours, seem not to 
result completely from a placebo effect; therefore further work is needed. This should not detract from the fact that our data 
were significantly affected by the placebo response of the patients, under conditions where they subjectively recorded their 
‘‘improvements.” Subjective measures resisted this, paradoxically reflecting both the positive and negative sides of this (and 
another motor signs [37]) study – patients ‘‘quality of life” may be at least partially improved, but this results simply from the 
expectation that the ‘‘treatment” will improve their situation, whereas more objective measures fail to see this improvement 
and quickly identify the placebo nature of these responses. 
5. Conclusions 
In conclusion, rTMS, under the stimulation parameters used in this study, has no direct therapeutic effect on sleep in PD, 
but given the scarcity of work assessing the putative therapeutic effect of the technique on Parkinsonian sleep it seems clear 
further studies are needed. Future studies should control for effects of a placebo response. Also, protocols presented here and 
by others [21] should be extended to polysomnography. 
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